Australia markets open in 3 hours 2 minutes
  • ALL ORDS

    7,281.10
    -50.50 (-0.69%)
     
  • AUD/USD

    0.7726
    -0.0118 (-1.50%)
     
  • ASX 200

    7,044.90
    -52.10 (-0.73%)
     
  • OIL

    65.77
    +0.49 (+0.75%)
     
  • GOLD

    1,815.20
    -20.90 (-1.14%)
     
  • BTC-AUD

    70,495.82
    -3,536.62 (-4.78%)
     
  • CMC Crypto 200

    1,473.92
    -89.91 (-5.75%)
     

Global Topical Drug Delivery Market to Reach $129.9 Billion by 2027

ReportLinker
·27-min read

Abstract: - Global Topical Drug Delivery Market to Reach $129. 9 Billion by 2027. - Amid the COVID-19 crisis, the global market for Topical Drug Delivery estimated at US$92.

New York, April 21, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Topical Drug Delivery Industry" - https://www.reportlinker.com/p06033143/?utm_source=GNW
4 Billion in the year 2020, is projected to reach a revised size of US$129.9 Billion by 2027, growing at a CAGR of 5% over the analysis period 2020-2027. Semi-Solid Formulations, one of the segments analyzed in the report, is projected to record a 5.1% CAGR and reach US$51.1 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Liquid Formulations segment is readjusted to a revised 4.6% CAGR for the next 7-year period.
- The U.S. Market is Estimated at $27.2 Billion, While China is Forecast to Grow at 4.7% CAGR
- The Topical Drug Delivery market in the U.S. is estimated at US$27.2 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$22.9 Billion by the year 2027 trailing a CAGR of 4.7% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.8% and 3.9% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.1% CAGR.
- Solid Formulations Segment to Record 4.4% CAGR
- In the global Solid Formulations segment, USA, Canada, Japan, China and Europe will drive the 4.4% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$14.1 Billion in the year 2020 will reach a projected size of US$19.1 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$14.9 Billion by the year 2027.

- Select Competitors (Total 43 Featured) -

  • 3M

  • Acrux Limited

  • Bayer AG

  • Biofarmitalia s.r.l

  • Cipla Inc.

  • Crescita Therapeutics Inc.

  • Galderma S.A.

  • GlaxoSmithKline plc

  • Janssen Global Services, LLC

  • Lohmann Therapie-Systeme AG

  • Medpharm

  • Mylan N.V.

  • Nitto Denko Corporation

  • Novartis AG

  • Pharmatek Laboratories, Inc.

  • Pocono Coated Products LLC

  • Skinvisible Pharmaceuticals, Inc.

  • Stiefel Laboratories, Inc.

  • Tapemark

  • Valeant Pharmaceuticals International, Inc.

  • West Pharmaceutical Services, Inc.




Read the full report: https://www.reportlinker.com/p06033143/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Topical Drug
Delivery by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR

Table 2: World Historic Review for Topical Drug Delivery by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 3: World 15-Year Perspective for Topical Drug Delivery by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets for Years 2012, 2020 & 2027

Table 4: World Current & Future Analysis for Semi-Solid
Formulations by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR

Table 5: World Historic Review for Semi-Solid Formulations by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 6: World 15-Year Perspective for Semi-Solid Formulations
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 7: World Current & Future Analysis for Liquid
Formulations by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR

Table 8: World Historic Review for Liquid Formulations by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 9: World 15-Year Perspective for Liquid Formulations by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 10: World Current & Future Analysis for Solid
Formulations by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR

Table 11: World Historic Review for Solid Formulations by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 12: World 15-Year Perspective for Solid Formulations by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 13: World Current & Future Analysis for Transdermal
Products by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR

Table 14: World Historic Review for Transdermal Products by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 15: World 15-Year Perspective for Transdermal Products by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 16: World Current & Future Analysis for Home Care
Settings by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR

Table 17: World Historic Review for Home Care Settings by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 18: World 15-Year Perspective for Home Care Settings by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 19: World Current & Future Analysis for Hospitals &
Clinics by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR

Table 20: World Historic Review for Hospitals & Clinics by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 21: World 15-Year Perspective for Hospitals & Clinics by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 22: World Current & Future Analysis for Burn Centers by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR

Table 23: World Historic Review for Burn Centers by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 24: World 15-Year Perspective for Burn Centers by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 25: World Current & Future Analysis for Other End-Uses by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR

Table 26: World Historic Review for Other End-Uses by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 27: World 15-Year Perspective for Other End-Uses by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 28: World Current & Future Analysis for Dermal Drug
Delivery by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR

Table 29: World Historic Review for Dermal Drug Delivery by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 30: World 15-Year Perspective for Dermal Drug Delivery by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 31: World Current & Future Analysis for Nasal Drug
Delivery by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR

Table 32: World Historic Review for Nasal Drug Delivery by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 33: World 15-Year Perspective for Nasal Drug Delivery by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 34: World Current & Future Analysis for Ophthalmic Drug
Delivery by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR

Table 35: World Historic Review for Ophthalmic Drug Delivery by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 36: World 15-Year Perspective for Ophthalmic Drug
Delivery by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World for Years 2012, 2020 & 2027

Table 37: World Current & Future Analysis for Rectal Drug
Delivery by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR

Table 38: World Historic Review for Rectal Drug Delivery by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 39: World 15-Year Perspective for Rectal Drug Delivery by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 40: World Current & Future Analysis for Vaginal Drug
Delivery by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR

Table 41: World Historic Review for Vaginal Drug Delivery by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 42: World 15-Year Perspective for Vaginal Drug Delivery
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES
Table 43: USA Current & Future Analysis for Topical Drug
Delivery by Product - Semi-Solid Formulations, Liquid
Formulations, Solid Formulations and Transdermal Products -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 44: USA Historic Review for Topical Drug Delivery by
Product - Semi-Solid Formulations, Liquid Formulations, Solid
Formulations and Transdermal Products Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 45: USA 15-Year Perspective for Topical Drug Delivery by
Product - Percentage Breakdown of Value Sales for Semi-Solid
Formulations, Liquid Formulations, Solid Formulations and
Transdermal Products for the Years 2012, 2020 & 2027

Table 46: USA Current & Future Analysis for Topical Drug
Delivery by End-Use - Home Care Settings, Hospitals & Clinics,
Burn Centers and Other End-Uses - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 47: USA Historic Review for Topical Drug Delivery by
End-Use - Home Care Settings, Hospitals & Clinics, Burn Centers
and Other End-Uses Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 48: USA 15-Year Perspective for Topical Drug Delivery by
End-Use - Percentage Breakdown of Value Sales for Home Care
Settings, Hospitals & Clinics, Burn Centers and Other End-Uses
for the Years 2012, 2020 & 2027

Table 49: USA Current & Future Analysis for Topical Drug
Delivery by Route Of Administration - Dermal Drug Delivery,
Nasal Drug Delivery, Ophthalmic Drug Delivery, Rectal Drug
Delivery and Vaginal Drug Delivery - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 50: USA Historic Review for Topical Drug Delivery by
Route Of Administration - Dermal Drug Delivery, Nasal Drug
Delivery, Ophthalmic Drug Delivery, Rectal Drug Delivery and
Vaginal Drug Delivery Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 51: USA 15-Year Perspective for Topical Drug Delivery by
Route Of Administration - Percentage Breakdown of Value Sales
for Dermal Drug Delivery, Nasal Drug Delivery, Ophthalmic Drug
Delivery, Rectal Drug Delivery and Vaginal Drug Delivery for
the Years 2012, 2020 & 2027

CANADA
Table 52: Canada Current & Future Analysis for Topical Drug
Delivery by Product - Semi-Solid Formulations, Liquid
Formulations, Solid Formulations and Transdermal Products -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 53: Canada Historic Review for Topical Drug Delivery by
Product - Semi-Solid Formulations, Liquid Formulations, Solid
Formulations and Transdermal Products Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 54: Canada 15-Year Perspective for Topical Drug Delivery
by Product - Percentage Breakdown of Value Sales for Semi-Solid
Formulations, Liquid Formulations, Solid Formulations and
Transdermal Products for the Years 2012, 2020 & 2027

Table 55: Canada Current & Future Analysis for Topical Drug
Delivery by End-Use - Home Care Settings, Hospitals & Clinics,
Burn Centers and Other End-Uses - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 56: Canada Historic Review for Topical Drug Delivery by
End-Use - Home Care Settings, Hospitals & Clinics, Burn Centers
and Other End-Uses Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 57: Canada 15-Year Perspective for Topical Drug Delivery
by End-Use - Percentage Breakdown of Value Sales for Home Care
Settings, Hospitals & Clinics, Burn Centers and Other End-Uses
for the Years 2012, 2020 & 2027

Table 58: Canada Current & Future Analysis for Topical Drug
Delivery by Route Of Administration - Dermal Drug Delivery,
Nasal Drug Delivery, Ophthalmic Drug Delivery, Rectal Drug
Delivery and Vaginal Drug Delivery - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 59: Canada Historic Review for Topical Drug Delivery by
Route Of Administration - Dermal Drug Delivery, Nasal Drug
Delivery, Ophthalmic Drug Delivery, Rectal Drug Delivery and
Vaginal Drug Delivery Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 60: Canada 15-Year Perspective for Topical Drug Delivery
by Route Of Administration - Percentage Breakdown of Value
Sales for Dermal Drug Delivery, Nasal Drug Delivery, Ophthalmic
Drug Delivery, Rectal Drug Delivery and Vaginal Drug Delivery
for the Years 2012, 2020 & 2027

JAPAN
Table 61: Japan Current & Future Analysis for Topical Drug
Delivery by Product - Semi-Solid Formulations, Liquid
Formulations, Solid Formulations and Transdermal Products -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 62: Japan Historic Review for Topical Drug Delivery by
Product - Semi-Solid Formulations, Liquid Formulations, Solid
Formulations and Transdermal Products Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 63: Japan 15-Year Perspective for Topical Drug Delivery
by Product - Percentage Breakdown of Value Sales for Semi-Solid
Formulations, Liquid Formulations, Solid Formulations and
Transdermal Products for the Years 2012, 2020 & 2027

Table 64: Japan Current & Future Analysis for Topical Drug
Delivery by End-Use - Home Care Settings, Hospitals & Clinics,
Burn Centers and Other End-Uses - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 65: Japan Historic Review for Topical Drug Delivery by
End-Use - Home Care Settings, Hospitals & Clinics, Burn Centers
and Other End-Uses Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 66: Japan 15-Year Perspective for Topical Drug Delivery
by End-Use - Percentage Breakdown of Value Sales for Home Care
Settings, Hospitals & Clinics, Burn Centers and Other End-Uses
for the Years 2012, 2020 & 2027

Table 67: Japan Current & Future Analysis for Topical Drug
Delivery by Route Of Administration - Dermal Drug Delivery,
Nasal Drug Delivery, Ophthalmic Drug Delivery, Rectal Drug
Delivery and Vaginal Drug Delivery - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 68: Japan Historic Review for Topical Drug Delivery by
Route Of Administration - Dermal Drug Delivery, Nasal Drug
Delivery, Ophthalmic Drug Delivery, Rectal Drug Delivery and
Vaginal Drug Delivery Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 69: Japan 15-Year Perspective for Topical Drug Delivery
by Route Of Administration - Percentage Breakdown of Value
Sales for Dermal Drug Delivery, Nasal Drug Delivery, Ophthalmic
Drug Delivery, Rectal Drug Delivery and Vaginal Drug Delivery
for the Years 2012, 2020 & 2027

CHINA
Table 70: China Current & Future Analysis for Topical Drug
Delivery by Product - Semi-Solid Formulations, Liquid
Formulations, Solid Formulations and Transdermal Products -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 71: China Historic Review for Topical Drug Delivery by
Product - Semi-Solid Formulations, Liquid Formulations, Solid
Formulations and Transdermal Products Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 72: China 15-Year Perspective for Topical Drug Delivery
by Product - Percentage Breakdown of Value Sales for Semi-Solid
Formulations, Liquid Formulations, Solid Formulations and
Transdermal Products for the Years 2012, 2020 & 2027

Table 73: China Current & Future Analysis for Topical Drug
Delivery by End-Use - Home Care Settings, Hospitals & Clinics,
Burn Centers and Other End-Uses - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 74: China Historic Review for Topical Drug Delivery by
End-Use - Home Care Settings, Hospitals & Clinics, Burn Centers
and Other End-Uses Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 75: China 15-Year Perspective for Topical Drug Delivery
by End-Use - Percentage Breakdown of Value Sales for Home Care
Settings, Hospitals & Clinics, Burn Centers and Other End-Uses
for the Years 2012, 2020 & 2027

Table 76: China Current & Future Analysis for Topical Drug
Delivery by Route Of Administration - Dermal Drug Delivery,
Nasal Drug Delivery, Ophthalmic Drug Delivery, Rectal Drug
Delivery and Vaginal Drug Delivery - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 77: China Historic Review for Topical Drug Delivery by
Route Of Administration - Dermal Drug Delivery, Nasal Drug
Delivery, Ophthalmic Drug Delivery, Rectal Drug Delivery and
Vaginal Drug Delivery Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 78: China 15-Year Perspective for Topical Drug Delivery
by Route Of Administration - Percentage Breakdown of Value
Sales for Dermal Drug Delivery, Nasal Drug Delivery, Ophthalmic
Drug Delivery, Rectal Drug Delivery and Vaginal Drug Delivery
for the Years 2012, 2020 & 2027

EUROPE
Table 79: Europe Current & Future Analysis for Topical Drug
Delivery by Geographic Region - France, Germany, Italy, UK and
Rest of Europe Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2020 through 2027 and % CAGR

Table 80: Europe Historic Review for Topical Drug Delivery by
Geographic Region - France, Germany, Italy, UK and Rest of
Europe Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 81: Europe 15-Year Perspective for Topical Drug Delivery
by Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK and Rest of Europe Markets for Years
2012, 2020 & 2027

Table 82: Europe Current & Future Analysis for Topical Drug
Delivery by Product - Semi-Solid Formulations, Liquid
Formulations, Solid Formulations and Transdermal Products -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 83: Europe Historic Review for Topical Drug Delivery by
Product - Semi-Solid Formulations, Liquid Formulations, Solid
Formulations and Transdermal Products Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 84: Europe 15-Year Perspective for Topical Drug Delivery
by Product - Percentage Breakdown of Value Sales for Semi-Solid
Formulations, Liquid Formulations, Solid Formulations and
Transdermal Products for the Years 2012, 2020 & 2027

Table 85: Europe Current & Future Analysis for Topical Drug
Delivery by End-Use - Home Care Settings, Hospitals & Clinics,
Burn Centers and Other End-Uses - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 86: Europe Historic Review for Topical Drug Delivery by
End-Use - Home Care Settings, Hospitals & Clinics, Burn Centers
and Other End-Uses Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 87: Europe 15-Year Perspective for Topical Drug Delivery
by End-Use - Percentage Breakdown of Value Sales for Home Care
Settings, Hospitals & Clinics, Burn Centers and Other End-Uses
for the Years 2012, 2020 & 2027

Table 88: Europe Current & Future Analysis for Topical Drug
Delivery by Route Of Administration - Dermal Drug Delivery,
Nasal Drug Delivery, Ophthalmic Drug Delivery, Rectal Drug
Delivery and Vaginal Drug Delivery - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 89: Europe Historic Review for Topical Drug Delivery by
Route Of Administration - Dermal Drug Delivery, Nasal Drug
Delivery, Ophthalmic Drug Delivery, Rectal Drug Delivery and
Vaginal Drug Delivery Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 90: Europe 15-Year Perspective for Topical Drug Delivery
by Route Of Administration - Percentage Breakdown of Value
Sales for Dermal Drug Delivery, Nasal Drug Delivery, Ophthalmic
Drug Delivery, Rectal Drug Delivery and Vaginal Drug Delivery
for the Years 2012, 2020 & 2027

FRANCE
Table 91: France Current & Future Analysis for Topical Drug
Delivery by Product - Semi-Solid Formulations, Liquid
Formulations, Solid Formulations and Transdermal Products -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 92: France Historic Review for Topical Drug Delivery by
Product - Semi-Solid Formulations, Liquid Formulations, Solid
Formulations and Transdermal Products Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 93: France 15-Year Perspective for Topical Drug Delivery
by Product - Percentage Breakdown of Value Sales for Semi-Solid
Formulations, Liquid Formulations, Solid Formulations and
Transdermal Products for the Years 2012, 2020 & 2027

Table 94: France Current & Future Analysis for Topical Drug
Delivery by End-Use - Home Care Settings, Hospitals & Clinics,
Burn Centers and Other End-Uses - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 95: France Historic Review for Topical Drug Delivery by
End-Use - Home Care Settings, Hospitals & Clinics, Burn Centers
and Other End-Uses Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 96: France 15-Year Perspective for Topical Drug Delivery
by End-Use - Percentage Breakdown of Value Sales for Home Care
Settings, Hospitals & Clinics, Burn Centers and Other End-Uses
for the Years 2012, 2020 & 2027

Table 97: France Current & Future Analysis for Topical Drug
Delivery by Route Of Administration - Dermal Drug Delivery,
Nasal Drug Delivery, Ophthalmic Drug Delivery, Rectal Drug
Delivery and Vaginal Drug Delivery - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 98: France Historic Review for Topical Drug Delivery by
Route Of Administration - Dermal Drug Delivery, Nasal Drug
Delivery, Ophthalmic Drug Delivery, Rectal Drug Delivery and
Vaginal Drug Delivery Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 99: France 15-Year Perspective for Topical Drug Delivery
by Route Of Administration - Percentage Breakdown of Value
Sales for Dermal Drug Delivery, Nasal Drug Delivery, Ophthalmic
Drug Delivery, Rectal Drug Delivery and Vaginal Drug Delivery
for the Years 2012, 2020 & 2027

GERMANY
Table 100: Germany Current & Future Analysis for Topical Drug
Delivery by Product - Semi-Solid Formulations, Liquid
Formulations, Solid Formulations and Transdermal Products -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 101: Germany Historic Review for Topical Drug Delivery by
Product - Semi-Solid Formulations, Liquid Formulations, Solid
Formulations and Transdermal Products Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 102: Germany 15-Year Perspective for Topical Drug
Delivery by Product - Percentage Breakdown of Value Sales for
Semi-Solid Formulations, Liquid Formulations, Solid
Formulations and Transdermal Products for the Years 2012, 2020 &
2027

Table 103: Germany Current & Future Analysis for Topical Drug
Delivery by End-Use - Home Care Settings, Hospitals & Clinics,
Burn Centers and Other End-Uses - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 104: Germany Historic Review for Topical Drug Delivery by
End-Use - Home Care Settings, Hospitals & Clinics, Burn Centers
and Other End-Uses Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 105: Germany 15-Year Perspective for Topical Drug
Delivery by End-Use - Percentage Breakdown of Value Sales for
Home Care Settings, Hospitals & Clinics, Burn Centers and Other
End-Uses for the Years 2012, 2020 & 2027

Table 106: Germany Current & Future Analysis for Topical Drug
Delivery by Route Of Administration - Dermal Drug Delivery,
Nasal Drug Delivery, Ophthalmic Drug Delivery, Rectal Drug
Delivery and Vaginal Drug Delivery - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 107: Germany Historic Review for Topical Drug Delivery by
Route Of Administration - Dermal Drug Delivery, Nasal Drug
Delivery, Ophthalmic Drug Delivery, Rectal Drug Delivery and
Vaginal Drug Delivery Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 108: Germany 15-Year Perspective for Topical Drug
Delivery by Route Of Administration - Percentage Breakdown of
Value Sales for Dermal Drug Delivery, Nasal Drug Delivery,
Ophthalmic Drug Delivery, Rectal Drug Delivery and Vaginal Drug
Delivery for the Years 2012, 2020 & 2027

ITALY
Table 109: Italy Current & Future Analysis for Topical Drug
Delivery by Product - Semi-Solid Formulations, Liquid
Formulations, Solid Formulations and Transdermal Products -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 110: Italy Historic Review for Topical Drug Delivery by
Product - Semi-Solid Formulations, Liquid Formulations, Solid
Formulations and Transdermal Products Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 111: Italy 15-Year Perspective for Topical Drug Delivery
by Product - Percentage Breakdown of Value Sales for Semi-Solid
Formulations, Liquid Formulations, Solid Formulations and
Transdermal Products for the Years 2012, 2020 & 2027

Table 112: Italy Current & Future Analysis for Topical Drug
Delivery by End-Use - Home Care Settings, Hospitals & Clinics,
Burn Centers and Other End-Uses - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 113: Italy Historic Review for Topical Drug Delivery by
End-Use - Home Care Settings, Hospitals & Clinics, Burn Centers
and Other End-Uses Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 114: Italy 15-Year Perspective for Topical Drug Delivery
by End-Use - Percentage Breakdown of Value Sales for Home Care
Settings, Hospitals & Clinics, Burn Centers and Other End-Uses
for the Years 2012, 2020 & 2027

Table 115: Italy Current & Future Analysis for Topical Drug
Delivery by Route Of Administration - Dermal Drug Delivery,
Nasal Drug Delivery, Ophthalmic Drug Delivery, Rectal Drug
Delivery and Vaginal Drug Delivery - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 116: Italy Historic Review for Topical Drug Delivery by
Route Of Administration - Dermal Drug Delivery, Nasal Drug
Delivery, Ophthalmic Drug Delivery, Rectal Drug Delivery and
Vaginal Drug Delivery Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 117: Italy 15-Year Perspective for Topical Drug Delivery
by Route Of Administration - Percentage Breakdown of Value
Sales for Dermal Drug Delivery, Nasal Drug Delivery, Ophthalmic
Drug Delivery, Rectal Drug Delivery and Vaginal Drug Delivery
for the Years 2012, 2020 & 2027

UNITED KINGDOM
Table 118: UK Current & Future Analysis for Topical Drug
Delivery by Product - Semi-Solid Formulations, Liquid
Formulations, Solid Formulations and Transdermal Products -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 119: UK Historic Review for Topical Drug Delivery by
Product - Semi-Solid Formulations, Liquid Formulations, Solid
Formulations and Transdermal Products Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 120: UK 15-Year Perspective for Topical Drug Delivery by
Product - Percentage Breakdown of Value Sales for Semi-Solid
Formulations, Liquid Formulations, Solid Formulations and
Transdermal Products for the Years 2012, 2020 & 2027

Table 121: UK Current & Future Analysis for Topical Drug
Delivery by End-Use - Home Care Settings, Hospitals & Clinics,
Burn Centers and Other End-Uses - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 122: UK Historic Review for Topical Drug Delivery by
End-Use - Home Care Settings, Hospitals & Clinics, Burn Centers
and Other End-Uses Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 123: UK 15-Year Perspective for Topical Drug Delivery by

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p06033143/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001